Summit Therapeutics Inc. (SMMT)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q2-2026 | 8-K (2026-07-23) · 99.1 · 99.2 | ||
| 10-Q | Q1-2026 | 8-K (2026-04-30) · 99.1 | ||
| 10-KLatest | FY-2025 | 8-K (2026-02-23) · 99.1 · 99.2 | 8-K (2026-01-12) · 99.1 · 99.2 · 99.3 | ||
| 10-Q | Q3-2025 | 8-K (2025-10-20) · 99.1 · 99.2 · 99.3 · 99.4 | ||
| 10-Q | Q2-2025 | 8-K (2025-08-11) · 99.1 | ||
| 10-Q | Q1-2025 | 8-K (2025-05-01) · 99.1 · 99.2 | ||
| 10-K | FY-2024 | 8-K (2025-02-24) · 99.1 · 99.2 | 8-K (2025-01-13) · 99.1 | ||
| 10-Q | Q3-2024 | 8-K (2024-10-30) · 99.1 · 99.2 | ||
| 10-Q | Q2-2024 | 8-K (2024-08-06) · 99.1 · 99.2 | ||
| 10-Q | Q1-2024 | 8-K (2024-05-01) · 99.1 · 99.2 | ||
| 10-K | FY-2023 | 8-K (2024-02-20) · 99.1 · 99.2 | 8-K (2024-01-08) · 99.1 · 99.2 | ||
| 10-Q | Q3-2023 | 8-K (2023-11-07) · 99.1 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Cover | ||
| Audit Information | — |
|
| Statements | ||
| Consolidated Balance Sheets | ||
| Consolidated Balance Sheets (P) | ||
| Consolidated Statements of Operations and Comprehensive Loss | ||
| Consolidated Statements of Stockholders' Equity | ||
| Consolidated Statements of Stockholders' Equity (P) | ||
| Consolidated Statements of Cash Flows | ||
| Notes | ||
| Akeso Collaboration and License Agreement | — |
|
| Akeso License and Collaboration Agreement | ||
| Basis of Presentation and Use of Estimates | ||
| Basis of Presentation, Use of Estimates, and Risks and Uncertainties | ||
| Commitments and Contingencies | ||
| Cybersecurity Risk Management and Strategy Disclosure | — |
|
| Fair Value Measurements and Investments | — |
|
| Fair Value Measurements and Short-term Investments | ||
| Goodwill | ||
| Goodwill and Intangible Assets | ||
| Income Tax | — |
|
| Insider Trading Arrangements | ||
| Insider Trading Policies and Procedures | — |
|
| Leases | ||
| Liquidity and Capital Resources | ||
| Loss Per Share | — |
|
| Nature of Business and Operations | — |
|
| Nature of Business and Operations and Recent Events | ||
| Net Loss Per Share | ||
| Organization | ||
| Other (expense) Income, Net | ||
| Other Expense, Net | — |
|
| Other Income | — |
|
| Other Income (expense), Net | ||
| Other Income, Net | ||
| Other Non-current Liabilities | — |
|
| Other Operating (expense) Income, Net | — |
|
| Other Operating Income (loss), Net | — |
|
| Other Operating Income, Net | ||
| Pay Vs Performance Disclosure | ||
| Promissory Note Payable To Related Parties | ||
| Property and Equipment | — |
|
| Recently Issued Or Adopted Accounting Pronouncements | ||
| Related Party Transactions | ||
| Research and Development Prepaid Expenses and Accrued Liabilities | ||
| Revenue | ||
| Segment Reporting | ||
| Stock-based Compensation | ||
| Stock-based Compensation and Warrants | — |
|
| Stockholders' Equity | ||
| Subsequent Events | — |
|
| Summary of Significant Accounting Policies | — |
|
| Summary of Significant Accounting Policies and Recent Accounting Pronouncements | ||
| Summary of Significant Accounting Policies and Recently Issued Or Adopted Accounting Pronouncements | — |
|